Similarly, Owonikoko et al. (84) investigated the PARP1 inhibitor veliparib in combination with DNA-damaging treatments including radiation in small cell lung cancer cells, and found that veliparib sensitized some cells to DNA damaging treatment. This evidence concerns the gene PARP1 and small cell lung carcinoma.